Why the study?
Does long-term therapy with elamipretide improve left ventricular and mitochondrial function in dogs with advanced heart failure?
Does long-term therapy with elamipretide improve left ventricular and mitochondrial function in dogs with advanced heart failure?
Elamipretide improves LV systolic function and reverses mitochondrial abnormalities in a canine model of advanced heart failure, supporting its further development for HF treatment.
Answers are grounded in this paper and cite their sources.
Supports elamipretide development in advanced HF; hypothesis-generating in animal model, warrants human trials.
Long-term therapy with elamipretide improves LV systolic function, normalizes plasma biomarkers, and reverses mitochondrial abnormalities in LV myocardium of dogs with advanced HF. The results support the development of elamipretide for the treatment of HF.
No takes yet. Share an insight, caveat, or question.
Sabbah et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: